Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

3.890 +0.090 (+2.37%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bioxcel Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
Why BioXcel Therapeutics Stock Is Getting Crushed Today
BioXcel just announced a big change. 
Via The Motley Fool
CLF Stock Alert: U.S. Steel Rejects Cleveland-Cliffs Bid
Cleveland-Cliffs (CLF) stock is worth checking on today after the company's takeover bill for United States Steel (X) was rejected. 
Via InvestorPlace
FFIE Stock Alert: Faraday Future Delivers Its First FF 91
Faraday Future (FFIE) stock is a hot topic on Monday after the EV company delivered its first FF 91 2.0 Futurist Alliance. 
Via InvestorPlace
PYPL Stock Alert: What to Know as PayPal Names New CEO
PayPal (PYPL) stock is in the news Monday as investors react to the finance transfer company naming Alex Chriss as its next CEO. 
Via InvestorPlace
Why Is BioXcel Therapeutics (BTAI) Stock Down 46% Today?
BioXcel Therapeutics (BTAI) stock is taking a beating on Monday after the biopharmaceutical company announced major layoffs. 
Via InvestorPlace
Dow Falls 50 Points; Monday.com Posts Upbeat Results
U.S. stocks traded mostly lower this morning, with the Dow Jones falling around 50 points on Monday. Following the market opening Monday, The Dow traded down 0.14% to 35,230.38 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
A Preview Of BioXcel Therapeutics's Earnings
Via Benzinga
Analyst Ratings for BioXcel Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
Via Benzinga
Analyst Expectations for BioXcel Therapeutics's Future
Via Benzinga
3 Biotech Stocks to Sell Before They Damage Your Portfolio
With the Street generally bearish towards the biotech sector, investors need to identify biotech stocks to avoid at this point. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why BioXcel Therapeutics Stock Was Bouncing Back This Week
What a difference a handful of trading days has made for the company. 
Via The Motley Fool
Levi Strauss, Riot Platforms And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Affirm Holdings, Applied Digital And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Dow Jones dropping more than 450 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day off right with a breakdown of the biggest pre-market stock movers traders need to watch on Thursday! 
Via InvestorPlace
Perion Network And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Drops 150 Points; US Factory Orders Increase 0.3% In May
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.46% to 34,259.45 while the NASDAQ fell... 
Via Benzinga
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Allarity Therapeutics, Inc. (NASDAQ: ALLR) shares surged 87% to $11.78 after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in... 
Via Benzinga
Wells Fargo To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
Jefferies boosted the price target for ACM Research, Inc. (NASDAQ: ACMR) from $9 to $23.4. Jefferies analyst Nick Cheng upgraded the stock from Underperform to Buy. ACM Research shares fell 2.2% to... 
Via Benzinga
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review
Major indexes rebounded strongly and many stocks flashed buy signals. 
Via Investor's Business Daily
Nasdaq Moves Lower; Acuity Brands Earnings Top Estimates
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday. The Dow traded up 0.68% to 34,081.83 while the NASDAQ fell 0.23% to 13,560.57. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Dow Up Triple Digits After Bank Stress Test, GDP Revision
The Dow Jones Industrial Average is up 194 points midday, while the S&P 500 Index and Nasdaq Composite move cautiously higher. 
Via Talk Markets
Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash. 
Via Benzinga
Crude Oil Edges Higher; McCormick Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Thursday. The Dow traded up 0.64% to 34,069.87 while the NASDAQ rose 0.13% to 13,609.09. The S&P... 
Via Benzinga
Why Shares of BioXcel Therapeutics Are Plunging Thursday
Questions regarding the safety of an Alzheimer's disease agitation therapy were raised when the company announced phase 3 trial results. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.